Posted by Michael Wonder on 06 Nov 2022
Moderna receives Health Canada authorisation for second Omicron targeting bivalent booster
4 November 2022 - mRNA-1273.222 targets BA.4/BA.5 Omicron sub-variants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which targets the Omicron BA.1 sub-variant.
Moderna today announced Health Canada has authorised the use of its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, as a booster dose for active immunisation against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older.
